[go: up one dir, main page]

PE20181450A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer

Info

Publication number
PE20181450A1
PE20181450A1 PE2018001021A PE2018001021A PE20181450A1 PE 20181450 A1 PE20181450 A1 PE 20181450A1 PE 2018001021 A PE2018001021 A PE 2018001021A PE 2018001021 A PE2018001021 A PE 2018001021A PE 20181450 A1 PE20181450 A1 PE 20181450A1
Authority
PE
Peru
Prior art keywords
compounds
cancer
thadiazole
treatment
hydrogen
Prior art date
Application number
PE2018001021A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
Mark David Charles
James Matthew Wood
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of PE20181450A1 publication Critical patent/PE20181450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Referido a compuestos de formula (I), o una sal farmaceuticamente aceptable, en donde: Q es 5-metilpiridazin-3-ilo, 5-cloropiridazin-3-ilo, entre otros; R es hidrogeno, fluor o metoxi; R1 es hidrogeno, difluorometoxi, entre otros; y R2 es metilo o etilo. Estos, son compuestos de 1,3,4-tiadiazol sustituidos; en donde estos compuestos pueden inhibir la enzima glutaminasa, como la GLS1. Tambien se refiere a una composicion farmaceutica que comprende estos compuestos, y al uso de los mismos, para tratar o prevenir enfermedades mediadas por GLS1, incluido el cancer.
PE2018001021A 2015-11-30 2016-11-30 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer PE20181450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
PE20181450A1 true PE20181450A1 (es) 2018-09-12

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001021A PE20181450A1 (es) 2015-11-30 2016-11-30 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer

Country Status (25)

Country Link
US (1) US9938265B2 (es)
EP (1) EP3383871B1 (es)
JP (1) JP6873132B2 (es)
KR (1) KR20180083412A (es)
CN (1) CN108349967B (es)
AR (1) AR106876A1 (es)
AU (1) AU2016363719B2 (es)
BR (1) BR112018010812A2 (es)
CA (1) CA3005516C (es)
CL (1) CL2018001408A1 (es)
CO (1) CO2018006929A2 (es)
DK (1) DK3383871T3 (es)
DO (1) DOP2018000134A (es)
EA (1) EA201891240A1 (es)
ES (1) ES2759940T3 (es)
IL (1) IL258644A (es)
MX (1) MX2018006528A (es)
NI (1) NI201800065A (es)
PE (1) PE20181450A1 (es)
PH (1) PH12018501132A1 (es)
SG (1) SG11201803813UA (es)
SV (1) SV2018005701A (es)
TN (1) TN2018000126A1 (es)
TW (1) TW201730188A (es)
WO (1) WO2017093300A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2010121918A1 (en) * 2009-04-20 2010-10-28 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
HRP20192144T1 (hr) * 2011-11-21 2020-02-21 Calithera Biosciences Inc. Heterociklični inhibitori glutaminaze
LT2920168T (lt) * 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6666263B2 (ja) * 2014-01-06 2020-03-13 ライゼン・ファーマシューティカルズ・エスアー グルタミナーゼの新規阻害剤
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
EA201891240A1 (ru) 2018-11-30
KR20180083412A (ko) 2018-07-20
JP6873132B2 (ja) 2021-05-19
DK3383871T3 (da) 2019-12-16
EP3383871A1 (en) 2018-10-10
MX2018006528A (es) 2019-05-15
PH12018501132A1 (en) 2019-01-21
CL2018001408A1 (es) 2018-10-12
AU2016363719A1 (en) 2018-07-05
TW201730188A (zh) 2017-09-01
CO2018006929A2 (es) 2018-10-10
JP2019501134A (ja) 2019-01-17
AU2016363719A8 (en) 2018-07-12
EP3383871B1 (en) 2019-09-11
CN108349967A (zh) 2018-07-31
DOP2018000134A (es) 2018-06-30
ES2759940T8 (es) 2020-05-20
CA3005516C (en) 2024-04-16
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
CA3005516A1 (en) 2017-06-08
IL258644A (en) 2018-06-28
TN2018000126A1 (en) 2019-10-04
AR106876A1 (es) 2018-02-28
BR112018010812A2 (pt) 2018-11-27
SV2018005701A (es) 2018-11-27
US20170152254A1 (en) 2017-06-01
AU2016363719B2 (en) 2019-11-14
SG11201803813UA (en) 2018-06-28
CN108349967B (zh) 2022-02-15
NI201800065A (es) 2018-10-18
ES2759940T3 (es) 2020-05-12

Similar Documents

Publication Publication Date Title
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2021009673A (es) Moduladores de ror-gamma.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018002060A2 (es) Compuestos farmacéuticos
CU20170154A7 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
UY36285A (es) Compuestos que inhiben la proteína mcl-1
MX2018009645A (es) Derivados haloalilamina indol y azaindol como inhibidores de lisil-oxidasas y sus usos.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
UY36207A (es) Inhibidores de la syk
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
EA201591649A1 (ru) Составы с органическими соединениями
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso